Dr. Anna Marie Kenney, Memorial Sloan Kettering Cancer Center, New York The Childhood Brain Tumor Foundation generously provided support to my lab at Memorial Sloan-Kettering to conduct basic studies of cell biological events that may contribute to medulloblastoma occurrence and growth. Our studies were called “mRNA translation machinery in medulloblastoma”. We used a combination of …
Daniel W. Lee, MD, University of Virginia Cancer Center Charlottesville One-year study, final summary 2019 Dr. Lee and his lab set out to develop a brand new tool to effectively treat children with DIPG. Using Chimeric Antigen Receptor (CAR) T cells, a therapy he helped pioneer in children with refractory leukemia, Dr. Lee’s lab designed, …
Yin Wang, Ph.D. First-year Children’s National, DC; University of Maryland, Baltimore Two-year study, second year Dr. Wang’s group has made significant progress for their project, “A Novel Mechanism and Immediately-Translatable Targeted-Therapy for Group 3 Medulloblastoma”. Their completed studies have demonstrated that HIF1α is a driver for infant Group 3 medulloblastoma (G3MB) by reciprocal positive regulation …
Huadong Pei, Ph.D., The George Washington University New Funding Summary, first of two years Medulloblastoma is the most common and aggressive type of brain tumor in children. It originates in the back part of the brain called the cerebellum. In up to 1/3 of cases, it can spread to other parts of the brain and …
Carl D. Novina, M.D., Ph.D.Dana-Farber Cancer Institute NEW-first of two-years 2019-2020 “The central organizing idea of biology (dogma) is that DNA (the blueprint of a cell), makes RNA (a messenger of information contained in the DNA) which in turn makes proteins (which carry out the activities of a cell). Whereas most scientists and physicians study …
Brendan D. Price, Ph.D., Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA First–Year Funding Summary, going into the second-year Pediatric high-grade gliomas (pHGG) have few treatment options and most children diagnosed only survive for 1-2 years. Identifying new treatments is therefore of the highest priority. Work in the lab is focused …
Jian Teng, Ph.D., Massachusetts General Hospital one-year 2018-2019 final summary I want to take this opportunity to sincerely thank CBTF for your funding to my proposal of using a subset of quinoline methanol anti-malaria agents in killing pediatric brain cancer cells. This funding helps us get one step closer to our goal. With the funding …
Stephen C. Mack, Ph.D., Baylor College of Medicine, Texas Children’s one-year study, final summary We are grateful for support provided by the CBTF and funders that have allowed us to pursue our project on the characterizing “The Role of MOS Proto-Oncogene in H3.3K27M Diffuse Intrinsic Pontine Glioma”. Diffuse intrinsic pontine glioma (DIPG) remains a fatal …
Allison Martin, M.D. Medulloblastoma is the most common malignant brain tumor in children. In cases of relapsed or refractory disease there is no known curative therapy. To address this question we have generated fetal mouse brain cells that mimic the most aggressive phenotype of medulloblastoma called “anaplastic” when they are placed into the cerebellum of …